Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Dongsheng Pharmaceutical International Co. Granted Exclusive Sales Rights for Thymosin Alpha 1 Injection

January 4, 2011 By Bio-Medicine.Org

NEW YORK, Jan. 5, 2011 /PRNewswire-Asia/ — Dongsheng
Pharmaceutical International Co., Ltd. (the “Company”) (OTC
Bulletin Board:
DNGH) announced today that it has obtained the exclusive sales
rights of Thymosin Alpha 1 Injection in 19 provinces in China from
Shanghai Biochemistry Pharmaceutical Co. I.

The State Food and Drug Administration of China (the “SFDA”)
approved the manufacturing permit of Thymosin Alpha 1 Injection for
Shanghai Biochemistry Pharmaceutical Co. I on June 29, 2010.
Immediately after such approval, Shanghai Biochemistry submitted
the manufactured samples to the SFDA for quality check, which is a
necessary step to receive final approval for mass manufacturing. We
expect that the samples will pass the quality check in the next 3-6
months, at which time Thymosin Alpha 1 Injection will be granted
final approval for mass manufacturing.

Thymosin Alpha 1 Injection is an immune modifier that has been
proven to be effective in the treatment of chronic hepatitis B,
acute severe hepatitis, adjuvant therapy for tumor and immuno
compromised diseases. Thymosin Alpha 1 Injection has been admitted
into the China National Basic Medicine Coverage List, thereby
making it more affordable to consumers and potentially increasing
its demand.  In June 2010, Dongsheng commenced a marketing
campaign for Thymosin Alpha 1 Injection within its sales and
distribution network, and the response so far from potential
customers has been promising.

Mr. Zhu XiaoDong, CEO of Dongsheng Pharmaceutical International,
stated that, “Thymosin Alpha 1 is a high value and high margin
medicine.  Obtaining exclusive sales rights for this product
in 19 provinces represents another milestone that Dongsheng
Pharmaceutical has accomplished since it went public in March
2010.”  

About Dongsheng Pharmaceutical International Co.,
Ltd.

Headquartered in Cheng

‘/>”/>

SOURCE

Related Articles Read More >

Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I
Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech